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The effects of stobadine on purine metabolism in rats treated
with carbon tetrachloride

Nilüfer BAYRAKTAR1, Seda DUYGULU DEVAY2, Mine YAVUZ TAŞLIPINAR3, Suna ÖMEROĞLU4,
Seyhan GÜMÜŞLÜ2, Mustafa KAVUTÇU2, Orhan CANBOLAT2

Aim: The aim of the present study was to investigate the relationship between liver damage induced by carbon
tetrachloride (CCl4) and adenosine deaminase (ADA), 5’-nucleotidase (5’NT), xanthine oxidase (XO) enzyme activities,
and malondialdehyde (MDA) levels. The effect of stobadine on purine metabolism was also evaluated.
Materials and methods: This study measured the effect of CCl4 on ADA, 5’NT, XO enzyme activities, and MDA levels,
and measured the histopathologic changes in liver cells.
Results: Our research found that ADA, XO activities, and MDA levels increased in the CCl4 group when compared
with the control group. This was also supported by the histopathological changes in the CCl4 and CCl4+stobadine group
found when compared with the control group. Stobadine could not protect cells against CCl4 damage.
Conclusion: The present study helps explain the biochemical mechanisms of liver injury formed by CCl4 and shows
the relationship between the purine degradation pathway and CCl4-induced cellular toxic effect. Cellular damage is
dependent upon the biochemical response to increased purine degradation pathway enzyme activities, which also may
be responsible for decreasing liver cellular adenosine levels and S-adenosyl-methionine and increasing superoxide
anion and hydrogen peroxide levels. It is suggested that the inhibition of key enzymes of the purine degradation pathway
(particularly ADA and XO) may prevent liver damage.
Key words: CCl4, adenosine deaminase, 5’-nucleotidase, xanthine oxidase, malondialdehyde, S-adenosyl-methionine

Introduction
Exposure to high concentrations of carbon tetrachloride
(CCl4) degenerates the liver (1). Experiments have
been carried out to generate a CCl4-induced cirrhosis
model using experimental animals because of CCl4’s
selective hepatotoxic effect (2). Past studies have shown
that chronic exposure to CCl4 can induce cirrhosis by
causing the production of free radicals (3).

After the bioactivation of CCl4, the unstable free
radical molecule trichloromethyl (CCl3.-) is created
by hepatic microsomal cytochromes P450. CCl3.reacts very rapidly with O2 to yield CCl3O2 (4). Both
CCl3.- and CCl3O2 can form secondary structures
such as conjugated dienes, lipid hydroperoxides, and
malondialdehyde (MDA) (5). Both these free radicals
and lipid peroxidation injure the hepatocytes and
lead to necrosis (6).
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Degradation of purines and their nucleotides
occurs during the turnover of endogenous nucleic
acids and the degradation of ingested nucleic acids.
5’-Nucleotidase (5’NT), adenosine deaminase
(ADA), and xanthine oxidase (XO) are key enzymes
of the purine nucleotide degradation pathway (7,8).
5’NT has an important function in the protection of
the intracellular nucleotide pool because it regulates
levels of adenosine 5’-monophosphate (5’AMP)
and guanosine 5’-monophosphate (5’GMP), both
of which are main substrates for DNA metabolism
(8). 5’NT deficiency can cause many pathological
conditions such as spherocytic anemia and immune
system defects (9).
ADA is a key enzyme involved in the regulation
of the concentration of both intracellular and
extracellular adenosine and deoxyadenosine (10).
Increased ATP and deoxyATP nucleotide levels
cause the inhibition of the ribonucleotide reductase
enzyme, which is responsible for the regulation of the
deoxy form of nucleotides in cells (11). Adenosine,
the other substrate of ADA, has a key role in
S-adenosyl-methionine (SAM) synthesis. SAM is
critical for transmethylation and transsulfuration
reactions and glutathione synthesis (12). SAM is also
perceived as a precursor antioxidant molecule and as
a source of methyl groups for methylation reactions.
It is synthesized in the presence of methionine
plus adenine (12,13). SAM has been shown to be
beneficial for alcoholic liver disease (14). Increased
ADA activity leads to the decrease of adenosine and
deoxyadenosine and results in the inhibition of SAM
synthesis (15).
ADA degrades adenosine-producing inosine.
Inosine is used by the purine nucleoside
phosphorylase (PNP) enzyme and is turned to
hypoxanthine. XO converts inosine to xanthine. XO
is the most important cellular source of enzymatic
radicals. XO leads to the formation of oxygen
radicals and hydrogen peroxide during the 2 steps
of hypoxanthine and xanthine utilization (16,17).
The structural change of xanthine dehydrogenase
(XD) to XO carries weight in the production of
enzymatic-based free radical damage (17). Sakuma et
al. suggested that monochloramine (NH2Cl) has the
potential to convert XD into XO in the liver, which
in turn may induce reactive oxygen species (ROS)
generation in the cell (18).

New antioxidants with different mechanisms have
been developed to prevent the formation of ROS or
to reduce their harmful effects, and stobadine (ST;
(-)-cis-2,8-dimethyl-2,3,4,4a,5,9b-hexa-hydro-1Hpyrido[4,3-b]indole) is one of these antioxidants
(19). Stobadine has been shown to be able to scavenge
hydroxyl, alkoxyl, and peroxyl radicals and prevent
superoxide radical generation. The antioxidant
properties of stobadine are conditioned mainly by its
indole ring compounds’ ability to stabilize radicals.
Thus, it reduces oxidative stress-induced lipid
peroxidation and protein oxidation (20,21).
In the present study, we examined the relationship
between CCl4 toxicity and purine degradation and
salvage pathway enzymes, which are responsible for
adenosine degradation and free radicals production.
We also investigated the protective role of stobadine
on this metabolism.
Materials and methods
This study was approved by the Experimental Ethics
Committee of Gazi University School of Medicine,
Ankara, Turkey, and the National Institute of Health’s
Guide for the Care and Use of Laboratory Animals was
followed.
Surgery and experimental protocol
In the present study, we used 40 Wistar albino (250300 g) rats that were housed in wire bottom cages,
given a free diet, and exposed to a 12-h light/dark
cycle. They were randomly assigned into 4 groups
containing 10 rats each. The groups were as follows:
group 1 was the control, group 2 was given stobadine,
group 3 was given CCl4, and group 4 was given
CCl4+stobadine. The rats in group 2 were given 24.7
mg/kg of stobadine daily dissolved in a 0.5% Avicel
(carboxymethyl cellulose) solution via orogastric
tube 3 times per week for 8 weeks (22,23). Group 3
rats were given CCl4 dissolved in olive oil at a ratio
of 1:10 (v/v) intraperitoneally 3 times a week at
levels of 0.3 mL/kg in the first week, 0.7 mL/kg in the
second week, and 1.0 mL/kg in the last 6 weeks for a
total of 8 weeks. The rats in group 4 were given 24.7
mg/kg of stobadine daily dissolved in a 0.5% Avicel
(carboxymethyl cellulose) solution via orogastric
tube, and also CCl4 dissolved in olive oil at a ratio
of 1:10 (v/v) intraperitoneally 3 times per week at
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levels of 0.3 mL/kg in the first week, 0.7 mL/kg in the
second week, and 1.0 mL/kg in the last 6 weeks for a
total of 8 weeks (24).
After 24 h had elapsed after the last administration
of drugs, all rats were sacrificed under general
anesthesia and muscle relaxant (40 mg/kg Alfamin
and 2.5 mg/kg Alfazyne intramuscularly). Next, their
livers were harvested and cleaned with a 0.9% NaCl
solution. The liver tissue samples were stored in a
10% formalin solution for histopathology analysis.
The remaining liver tissues were immediately frozen
in liquid nitrogen and stored in a freezer at −80 °C
until all measurements were complete.
Tissue preparation and analysis of liver enzyme
activities
The frozen liver tissues were homogenized in a 0.9%
NaCl solution. The homogenates were centrifuged at
16000 × g at 4 °C for 20 min. The protein content of
supernatants was measured according to the method
described by Lowry (25). 5’NT, ADA, and XO enzyme
activities in the liver tissues were also measured
according to the methods described by Donald et al.,
Guisti et al., and Hashimato et al., respectively (2628). All enzyme activities are presented as mIU/mg
protein. MDA levels were measured according to the
method described by Van Ye et al. (29). Results are
presented as μmol MDA/mg protein.
Histopathological evaluation
We used the Bio-Optica aniline blue staining
method applied to Masson’s trichrome stain in the
histopathological examination. (Bio-Optica Masson’s

trichrome, Cat. No. 04-010802, Milan, Italy).
In addition, tissues were evaluated by the
immunohistochemical method. For this, the
TGF-β3 antibody was used to examine the
immunohistochemical staining. A Leica DM 4000 B
microscope was used to evaluate liver fibrosis.
Statistical analysis
We used SPSS 15.0 for Windows and Microsoft Excel
for Windows XP to perform the statistical analyses
and create graphs. Data were presented as the mean ±
standard deviation (X ± SD). The Mann-Whitney U
test and Kruskal-Wallis variance analysis were used
for the statistical analyses. P < 0.01 was considered to
be significant.
Results
Our results are given in the Table. ADA and XO
activities were significantly increased in the CCl4 and
CCl4+stobadine groups compared with the control
and stobadine groups. Stobadine alone could not
approximate the activities of these 2 enzymes in
the control group or in the CCl4+stobadine group.
ADA and XO enzyme activities did not differ in the
CCl4 group as compared with the CCl4+stobadine
group. When stobadine was introduced in the
CCl4+stobadine group, the 5’NT enzyme activity
rose to that of the levels of the control group.
MDA levels significantly increased in the CCl4 and
CCl4+stobadine groups when compared with the
control group and the stobadine group. MDA levels

Table. 5’NT, ADA, and XO enzyme activities and MDA levels in rat liver tissue.
Groups
(n = 10)

5’NT
(mIU/mg prot.)

ADA
(mIU/mg prot.)

XO
(mIU/mg prot.)

MDA
(μmol/mg prot.)

Control

756.2 ± 116.1

20.8 ± 2.1

321.2 ± 112.1

10.4 ± 0.9

Stobadine

1171.7 ± 164.3a

23.6 ± 2.5

344.11 ± 103.3

10.1 ± 1.0

CCl4

714.1 ± 109.2b

220.9 ± 29.9 a,b

821.11 ± 84.2a,b

22.3 ± 2.5a,b

CCl4+stobadine

951.5 ± 188.7a,c

253.3 ± 23.4a,b

798.8 ± 72.3a,b

17.5 ± 1.6a,b,c

a

P < 0.01, compared with control group
P < 0.01, compared with stobadine group
c
P < 0.01, compared with CCl4 group
b
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were decreased in the CCl4+stobadine group as
compared with the CCl4 group.
Our histopathological results show that the portal
vein, branches of the hepatic artery, and the bile
duct around the arrangement of collagen fibers were
normal in the control group (Figure 1). Parenchymal
liver cells, sinusoids, and vascular structures close
to those of the control group were noticed in the
stobadine group (Figure 2). Developing advanced oil
necrosis, connective tissue cells leading to fibrosis,
and excessive collagen fibers were identified in the
CCl4 group (Figure 3). Less cellular necrosis and fatty
vacuole formation was seen in the CCl4+stobadine

group. However, continued signs of fibrosis were
observed in this group (Figure 4). In our study,
the immunohistochemical method of examining
stained liver tissue sections was also used. In the
control group, TGF-β3 immunoreactivity was found
to be weak (Figure 5). Histopathologic results were
similarly obtained in the stobadine group when
compared with the control group (Figure 6). TGF-β3
immune reactivity significantly increased in the liver
parenchymal cells and the septal structures in the
CCl4 group (Figure 7). Moderate immunoreactivity
of TGF-β3 was viewed in the CCl4+stobadine group
(Figure 8).

Figure 1. Control group: portal vein, branches of hepatic artery,
and bile duct around the arrangement of the collagen
fibers was normal (Masson’s trichrome, 400×).

Figure 2. Stobadine group: parenchymal liver cells, sinusoids,
and vascular structures close to the control group were
noticed (Masson’s trichrome, 400×).

Figure 3. CCl4 group: developing advanced oil necrosis,
connective tissue cells leading to fibrosis, and excessive
collagen fibers were identified (Masson’s trichrome,
400×).

Figure 4. CCl4+stobadine group: less cellular necrosis and fatty
vacuole formation was seen, but continued signs of
fibrosis were observed (Masson’s trichrome, 400×).
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Discussion
In our study, enzyme activities of the purine salvage
pathway were evaluated in rats administered with
CCl4. The amount of liver damage was further
supported by the results of the histopathological
examination of liver tissues stained with Masson’s
trichrome and by using the immunohistochemical
method. The changes in enzyme activities that may
arise with CCl4-induced damage will help us to
understand metabolism and produce solutions for
the problems that cause liver damage. In addition,
we investigated the effects of the new antioxidant
molecule stobadine on the purine salvage pathway,
which contains the most important enzymatic step of
free radical generation.

The most common chemical agent used to generate
liver damage is CCl4. It is widely used by researchers
who seek to understand the biochemical basis of
liver necrosis and fibrosis. Free radicals resulting
from the effects of toxins cause unsaturated fatty acid
peroxidation of cellular membrane phospholipids
that then lead to cellular necrosis (3-6). Many
antioxidant molecules are used in order to prevent
CCl4 toxicity. Stobadine prevents oxidation of –SH
groups and amino acids, and the formation of single
oxygen molecules. Stobadine can also neutralize
hydroxyl, peroxyl, and alkoxyl radicals (20,21).
Purine metabolism is important in providing a
substrate for SAM, which is perceived as a precursor
antioxidant molecule and a source of methyl groups
for methylation reactions (13,14). Studies show that

Figure 5. Control group: TGF-β3 immunoreactivity was found
to be weak (anti-TGF-β3, 400×).

Figure 6. Stobadine group: histopathologic results were similar
to the control group (anti-TGF-β3, 400×).

Figure 7. CCl4 group: TGF-β3 immunoreactivity was
significantly increased in the liver parenchymal cells
and the septal structures (anti-TGF-β3, 400×).

Figure 8. CCl4+stobadine group: moderate immunoreactivity of
TGF-β3 was seen (anti-TGF-β3, 400×).
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SAM protects against CCl4-induced liver damage
and alcohol toxicity (30,31). XO catalyses the final
enzymatic steps of the purine degradation pathway
and is responsible for cellular damage through
the production of oxygen radicals and hydrogen
peroxide. XO reactions are enzymatically the most
important oxygen radical producers in cells. It has
been suggested that NH2Cl has the potential to
convert XD into XO in the liver, which in turn may
induce ROS generation in cells (18).
In our study, it is important to note that CCl4
increased ADA and XO activities yet had no effect
on 5’NT activity. We suggest that the metabolic result
of this finding is reduced levels of adenosine and the
increase in oxygen radicals and hydrogen peroxide.
Increased adenosine destruction led to the increase
in the substrate for XO and thus an increase in
oxygen-based radicals. Histopathologic results of the
damage caused by CCl4 were fibrosis and necrosis of
the liver tissue, which were determined via Masson’s
trichrome and the immunohistochemical method.
These findings are important in defining cellular
damage caused by CCl4. Increased MDA levels
detected in the CCl4 and CCl4+stobadine groups as
compared with the other groups support the lipid
peroxidation and histopathologic results that showed
lipid membrane damage.

Increased ADA activity results in the reduction of
SAM metabolism and an increase in oxygen-based
free radicals. These 2 harmful effects are thought to
be mainly responsible for the damage caused by the
use of CCl4. The histopathologic demonstration of
ongoing damage in the CCl4+stobadine group led
to this hypothesis. Despite the partial adjustment
of cellular damage by stobadine during the use of
CCl4, cellular damage was still found. This shows that
stobadine has a limited protective effect and does
not prevent lipid peroxidation. Lower MDA levels
in the CCl4+stobadine group than the CCl4 group
may explain the partial recovery of cellular damage.
Higher MDA levels in the CCl4+stobadine group
than the control group support the histopathologic
results of our study. These results also may show
stobadine is an antioxidant molecule, but one that
has an inadequate protective effect on CCl4-based
radicals.
Our study is a pioneering step in research
regarding the effect of liver damage caused by CCl4
on the purine degradation pathway. In preventing
liver damage caused by CCl4, inhibiting key enzymes
of this pathway (in particular ADA and XO) may be
clinically significant.
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